The 'endocannabinoid system' is actually part of a much larger network — the endocannabinoidome — with 20+ receptors and dozens of signaling molecules, which explains why CBD works, why single-target drugs fail, and why cannabis affects so many systems.
Anyone who wants to understand why the endocannabinoid system is more complex and more important than the textbook version suggests.
20+ receptorsbeyond CB1 and CB2 that respond to cannabinoids and related lipid mediators — the endocannabinoidome is far larger than the classical ECS
The Backstory
For twenty years, the endocannabinoid system had a clean story. Two receptors: CB1 in the brain, CB2 in the immune system. Two signaling molecules: anandamide and 2-AG. A handful of enzymes to build and break them down. It fit on a textbook page. It was elegant. It was teachable.
It was also incomplete.
By 2018, the evidence had accumulated to the point where one of the field's most influential researchers felt compelled to redraw the map entirely. Vincenzo Di Marzo — the Italian-born chemist who had spent decades studying endocannabinoid metabolism — published a landmark review in Nature Reviews Drug Discovery, the world's highest-ranked drug discovery journal, arguing that the "endocannabinoid system" was actually part of something much larger.
He called it the endocannabinoidome.
The Problem With the Old Map
The classical ECS model worked beautifully — until it didn't. As researchers tried to develop drugs based on the two-receptor, two-molecule model, they kept running into problems that the map couldn't explain.
Evidence Matrix
The Failures That Forced a Rethink
| Study | Design | N | Finding | |
|---|---|---|---|---|
| ↔ | Rimonabant(2006) | CB1 blocker for obesity | ~13,000 | Effective for weight loss — but caused depression, anxiety, and suicidal ideation in 10% of patients. Pulled from European market in 2008. |
| ↔ | Taranabant(2008) | CB1 blocker for obesity | ~5,000 | Same problem as rimonabant: psychiatric adverse events. Development abandoned by Merck. |
| ↔ | BIA 10-2474(2016) | FAAH inhibitor (Phase I) | 6 | One participant died, four hospitalized with brain damage in a French clinical trial. The drug likely hit targets beyond FAAH. |
| ↑ | CBD (Epidiolex)(2018) | Anti-epileptic | 516 | FDA approved. Works effectively — but barely binds CB1 or CB2. The classical model can't explain its mechanism. |
Di Marzo (2018), Nat Rev Drug Discov; FDA.gov
The pattern was telling. Drugs designed to precisely target CB1 or CB2 kept producing unexpected effects — suggesting they were hitting parts of a system nobody had mapped. Meanwhile, CBD was working clinically despite the classical model saying it shouldn't, because it barely interacts with CB1 or CB2.
Something was missing from the picture.
The Endocannabinoidome
Di Marzo's answer was that the endocannabinoid system isn't a system at all — it's a subsystem, embedded within a much larger network of lipid signaling molecules, receptors, and enzymes.
Classical ECS (Textbook Version)
- 2 receptors: CB1, CB2
- 2 endocannabinoids: anandamide, 2-AG
- 5 key enzymes: FAAH, MAGL, DAGL-α, DAGL-β, NAPE-PLD
- Fits on one diagram
- Clean, elegant, targetable
Real but incomplete — like a subway map that only shows two lines
Endocannabinoidome (Actual System)
- 20+ receptors: CB1, CB2, GPR55, GPR18, GPR119, TRPV1, TRPV2, TRPA1, PPARα, PPARγ, and more
- 12+ lipid mediators: anandamide, 2-AG, PEA, OEA, oleamide, N-arachidonoyl-dopamine, and others
- Dozens of metabolic enzymes with overlapping substrates
- Interconnected with the gut microbiome
- Complex, messy, and much harder to drug
The actual territory — far more complex, but explains what the textbook version can't
Di Marzo (2018), Nat Rev Drug Discov 17:623-639
The term "endocannabinoidome" captured a simple but powerful idea: the molecules we call endocannabinoids don't operate in isolation. They're part of a family of lipid mediators — chemically related fatty molecules — that interact with a constellation of receptors far beyond CB1 and CB2. And these interactions aren't peripheral curiosities. They're central to how the system actually works.
Why This Explains CBD
Myth vs. Reality
CBD doesn't work because it doesn't bind to cannabinoid receptors.
CBD barely binds to CB1 or CB2 — the two 'cannabinoid receptors.' But the endocannabinoidome includes over 20 receptors that respond to cannabinoids and related molecules. CBD interacts with several of them: it activates TRPV1 (involved in pain perception), modulates GPR55 (involved in bone density and cancer cell proliferation), engages PPARγ (involved in inflammation), and inhibits FAAH (the enzyme that breaks down anandamide, effectively boosting your body's own endocannabinoid levels). CBD works — it just doesn't work through the receptors the textbook focused on.
The Evidence
CBD's clinical efficacy is established: FDA-approved for epilepsy (Epidiolex), with evidence in anxiety, psychosis, and inflammation. Its receptor profile includes TRPV1, 5-HT1A, GPR55, PPARγ, and FAAH modulation — all endocannabinoidome targets.
Di Marzo (2018), Nat Rev Drug Discov; Devinsky et al. (2017), NEJM
This was perhaps the most practically significant implication of the endocannabinoidome concept. For years, CBD skeptics had argued that it couldn't work because it doesn't bind CB1 or CB2. The endocannabinoidome showed that this argument was based on an incomplete map. CBD doesn't need CB1 or CB2 — it has an entire network of alternative targets.
It also explains why full-spectrum cannabis products sometimes produce different effects than isolated THC. When you consume whole-plant cannabis, dozens of compounds are interacting with the endocannabinoidome simultaneously — a fundamentally different pharmacological event than flooding CB1 with pure THC.
The Man Who Redrew the Map
Vincenzo Di Marzo trained as an organic chemist in Naples and spent decades at the Italian National Research Council (CNR) studying how endocannabinoids are made and broken down in cells. His lab was instrumental in characterizing the enzymes that synthesize and degrade 2-AG — the more abundant of the two classical endocannabinoids.
But Di Marzo was never satisfied with the clean two-receptor model. As his lab and others discovered more lipid mediators that interacted with cannabinoid-related receptors, and more receptors that responded to cannabinoid-like molecules, the boundary of the "endocannabinoid system" kept expanding. At some point, he realized the boundary was artificial — what existed wasn't a small system with neat borders but a large, interconnected network of lipid signaling that the field had been studying one piece at a time.
He coined the term "endocannabinoidome" to name what he was seeing. By 2018, the concept had matured enough — and the clinical failures had accumulated enough — for him to make the case in the field's most prominent review venue.
What Failed and Why
The endocannabinoidome concept doesn't just explain CBD. It explains the failures.
The Gut Connection
One of the most surprising aspects of the endocannabinoidome was its connection to the gut microbiome. Di Marzo highlighted emerging evidence that gut bacteria produce and respond to endocannabinoidome mediators — creating a signaling axis between the microbiome, the endocannabinoidome, and the brain.
This gut-endocannabinoidome-brain axis is now an active area of research, with implications for metabolic disease, mood disorders, and inflammatory conditions. It suggests that some of the effects of cannabis on appetite, nausea, and gut function may operate through this pathway rather than through direct CB1 activation in the brain.
What It Means Going Forward
2 → 20+
The number of receptors in the endocannabinoid system expanded tenfold when Di Marzo redrew the map. The classical model of 2 receptors, 2 endocannabinoids, and 5 enzymes gave way to a network of 20+ receptors, 12+ mediators, and dozens of enzymes — the endocannabinoidome.
This is comparable to discovering that the solar system, which you thought had 9 planets, actually has hundreds of objects worth studying. The original planets are still there — they're just part of something much bigger.
Di Marzo (2018), Nat Rev Drug Discov 17:623-639
The endocannabinoidome doesn't invalidate what we knew about the ECS — it extends it. CB1 and CB2 are still real and important. Anandamide and 2-AG are still the primary endocannabinoids. But they operate within a context that's far richer and more interconnected than the textbook version suggests.
For drug development, this means shifting from single-target precision drugs to strategies that work with the network — or, as Di Marzo noted, learning from botanical preparations like CBD that already engage multiple targets naturally.
For cannabis users, it means that the entourage effect has a plausible biological mechanism. When terpenes, minor cannabinoids, and CBD interact with a 20+ receptor network alongside THC, the pharmacological outcome is genuinely different from THC alone.
Related Research
From Simple System to Complex Network
The endocannabinoidome concept built on decades of incremental discovery. These studies laid the foundation.
The endocannabinoid system and the brain
Mechoulam & Parker (2013)
The definitive review of the classical ECS — the map Di Marzo expanded.
The endocannabinoid system as an emerging target of pharmacotherapy
Pacher, Bátkai & Kunos (2006)
Mapped every disease where the ECS plays a role — using the classical model that Di Marzo showed was incomplete.
The molecular logic of endocannabinoid signalling
Piomelli (2003)
The mechanistic framework for retrograde signaling — one piece of the larger endocannabinoidome puzzle.
GPR55: a novel cannabinoid receptor?
Ryberg et al. (2007)
One of the first 'non-classical' cannabinoid receptors identified — a harbinger of the expanded system Di Marzo described.
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects
Russo (2011)
Argued for multi-compound synergy — the endocannabinoidome provides the receptor network where that synergy could occur.
What is the endocannabinoidome?
The endocannabinoidome is the full network of receptors, signaling molecules, and enzymes involved in cannabinoid-related signaling in the body. It includes the classical endocannabinoid system (CB1, CB2, anandamide, 2-AG) plus over 20 additional receptors, dozens of lipid mediators, and numerous metabolic enzymes. The term was coined by Vincenzo Di Marzo to capture the actual complexity of what was previously called the "endocannabinoid system."
Why does this matter for cannabis users?
The endocannabinoidome explains why different cannabis products produce different effects. When you consume whole-plant cannabis, dozens of compounds interact with a 20+ receptor network — not just THC binding to CB1. This is why full-spectrum products, CBD, and different terpene profiles can produce meaningfully different experiences, and why isolating a single compound doesn't capture the full pharmacology of cannabis.
Does this prove the entourage effect?
It provides a plausible biological mechanism for it. If the relevant receptor network includes 20+ targets rather than 2, then multi-compound preparations (like whole-plant cannabis) have many more ways to interact with the system than single compounds (like pure THC). Whether specific entourage interactions have clinically meaningful effects is still being studied, but the endocannabinoidome shows that the concept is biologically plausible.
Why did cannabinoid drugs fail?
Drugs like rimonabant (a CB1 blocker for obesity) and BIA 10-2474 (a FAAH inhibitor) were designed using the classical two-receptor model. They targeted one component of what turned out to be a much larger network. Blocking CB1 globally caused psychiatric side effects because the endocannabinoidome connects appetite regulation to mood and stress. The FAAH inhibitor likely hit uncharacterized targets. The lesson: you can't safely target a system you haven't fully mapped.
What the researchers found
The classical endocannabinoid system — two receptors (CB1 and CB2), two endocannabinoids (anandamide and 2-AG), and a handful of enzymes — is part of a much larger network that Di Marzo termed the 'endocannabinoidome.' This expanded system includes over 20 receptors (including GPR55, TRPV1, PPARs), dozens of lipid mediators chemically related to endocannabinoids (like PEA, OEA, and oleamide), and the metabolic enzymes that produce and degrade them. The complexity explains why single-target cannabinoid drugs have often failed and why multi-target approaches — including botanical preparations like CBD — show more clinical promise.
Why it matters
This paper redefined the playing field for cannabinoid medicine. The endocannabinoidome concept explains puzzles that the classical ECS model couldn't: why CBD works despite barely binding CB1/CB2, why whole-plant cannabis often has different effects than isolated THC, and why rimonabant (a CB1 blocker) failed despite sound pharmacological logic. It shifted the therapeutic strategy from targeting single receptors to understanding and modulating a complex network.
The numbers in context
20+ receptors beyond CB1/CB2 (including GPR55, TRPV1, PPARγ, GPR18, GPR119)
12+ lipid mediators beyond anandamide and 2-AG
Dozens of metabolic enzymes
2 approved cannabinoid medicines by 2018: nabiximols (Sativex) and cannabidiol (Epidiolex)
How the study worked
Comprehensive review published in Nature Reviews Drug Discovery — the world's top-ranked drug discovery journal — examining the history, current state, and future directions of endocannabinoid-targeted therapeutics.
What this study cannot tell us
A narrative review reflecting one researcher's synthesis. Many proposed therapeutic strategies remain preclinical. The endocannabinoidome concept, while increasingly supported, is still being refined and debated regarding its exact boundaries.
How to read the evidence
A comprehensive review in Nature Reviews Drug Discovery (impact factor ~65), the highest-ranked drug discovery journal. Written by one of the most influential researchers in endocannabinoid science.
When this study was published
Published in 2018. The endocannabinoidome concept continues to be refined and expanded, with growing evidence for its role in gut-brain axis signaling and metabolic disease.
The bigger picture
The endocannabinoidome concept has reshaped cannabinoid drug development. Instead of trying to create precise single-target drugs (an approach that produced the disastrous rimonabant), researchers are now exploring multi-target strategies, FAAH inhibitors, and botanical preparations that interact with the broader network. The concept also provides a scientific framework for the entourage effect — the idea that cannabis compounds work better together than alone.
Questions still open
- How many components of the endocannabinoidome remain undiscovered?
- Can multi-target drugs be designed to modulate the endocannabinoidome without the side effects of single-target approaches?
- Does the endocannabinoidome concept fully explain why whole-plant cannabis often outperforms isolated compounds?
- How does gut microbiome signaling through the endocannabinoidome affect brain function?
Common questions
What is the endocannabinoidome?
Why does CBD work if it doesn't strongly bind CB1 or CB2 receptors?
Does this explain the entourage effect?
Read the original research
New approaches and challenges to targeting the endocannabinoid system.
Nature reviews. Drug discovery, 17(9), 623-639
The top-ranked drug discovery journal in the world. Publishes reviews of the most important developments in pharmaceutical science.
Citation
Di Marzo, Vincenzo. (2018). New approaches and challenges to targeting the endocannabinoid system.. Nature reviews. Drug discovery, 17(9), 623-639. https://doi.org/10.1038/nrd.2018.115
Explore the wider topic
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Full Spectrum vs Broad Spectrum vs Isolate: What the Labels Mean
- The Entourage Effect: Does Whole-Plant Cannabis Work Better Than Isolates
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body